Featured Research

from universities, journals, and other organizations

Investigational Drug Shows Promise In Ovarian Cancer

Date:
September 16, 2008
Source:
European Society for Medical Oncology (ESMO)
Summary:
An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to new research.

An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to a presentation at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

Prof. Michael Friedlander from Australia presented the results of an international collaborative trial which administered the drug to 35 patients with recurrent ovarian, fallopian tube or peritoneal carcinoma. At the ESMO Congress, he presented final results of the trial on behalf of his co-investigators.

Women who had already been treated with one or two previous chemotherapy regimens were eligible for the study provided they only had an elevated CA-125 or small tumors on scans. Each participant received 800mg of the oral drug daily, and the primary outcome measure was a decrease in blood levels of the protein CA-125.

CA-125 is a biological marker used to predict tumor recurrence and response to chemotherapy. Levels of the protein rise on average about 3 months before onset of symptoms or scan evidence of recurrence. Hence, it is an attractive marker to assess the efficacy of new agents such as pazopanib when the tumor volume is low.

The study showed that 31% of the patients had a greater than 50% decrease in CA-125 levels, with median duration of response at 113 days, Prof. Friedlander said. It was generally well tolerated, with a similar spectrum of side-effects seen with other angiogenesis inhibitors.

"Many patients with ovarian cancer will have a recurrence of cancer following initial chemotherapy,” he said. “This study clearly demonstrates that pazopanib is an active, well-tolerated drug for women with recurrent ovarian cancer.”

The findings of this study support further investigation of the potential role of pazopanib in the management of women with ovarian cancer, Prof. Friedlander added. An international phase III study investigating the drug for ovarian cancer will now go ahead.

“The majority of patients with ovarian cancer will have advanced disease at the time of initial diagnosis,” Prof. Friedlander said. “Typically, these patients are managed with surgery followed by combination chemotherapy. Unfortunately most patients will relapse usually within 2 years following the initial therapy. There is therefore a real need to investigate novel agents such as pazopanib to ensure new therapeutic options for patients with ovarian cancer.”


Story Source:

The above story is based on materials provided by European Society for Medical Oncology (ESMO). Note: Materials may be edited for content and length.


Cite This Page:

European Society for Medical Oncology (ESMO). "Investigational Drug Shows Promise In Ovarian Cancer." ScienceDaily. ScienceDaily, 16 September 2008. <www.sciencedaily.com/releases/2008/09/080915083717.htm>.
European Society for Medical Oncology (ESMO). (2008, September 16). Investigational Drug Shows Promise In Ovarian Cancer. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2008/09/080915083717.htm
European Society for Medical Oncology (ESMO). "Investigational Drug Shows Promise In Ovarian Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/09/080915083717.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins